- United Therapeutics‘ second-quarter revenue was $798.6 million, marking a year-over-year increase of 12%, aligning closely with estimates of $804.2 million.
- Net sales of Tyvaso reached $469.6 million, growing 18% from the previous year, just shy of the $481.4 million estimate.
- Remodulin sales fell by 8.6% year-over-year to $134.7 million, slightly below the projected $136.5 million.
- Orenitram saw a 16% increase in sales, totaling $123.9 million, surpassing the estimated $118.5 million.
- Unituxin sales increased by 13%, reaching $58.4 million, slightly above the $57.6 million estimate.
- Adcirca sales rose by 14% to $6.5 million, exceeding the anticipated $5.18 million.
- Earnings per share for the quarter were $6.41, compared to $5.85 in the previous year, though this fell short of the $7.09 estimate.
- Research and Development expenses were $134.0 million, a decrease of 4% year-over-year, and close to the estimated $133.3 million.
- CEO Martine Rothblatt emphasized the record-setting results driven by their strong commercial business.
- Current analyst recommendations include 9 buys, 4 holds, and 1 sell.
United Therapeutics on Smartkarma
Independent analyst coverage on United Therapeutics by Baptista Research on Smartkarma has been positive, with a bullish sentiment towards the company’s expansion into organ xenotransplantation. In a research report titled “United Therapeutics: Expansion into Organ Xenotransplantation to Position Itself As A Pioneer In This Emerging Domain!” the analyst highlights United Therapeutics‘ strong performance in the first quarter of 2025, reporting record revenue of $794 million. The company’s key products, including Tyvaso, Orenitram, Remodulin, and Unituxin, have shown consistent growth due to robust patient demand and increased prescriber engagement, with Tyvaso products demonstrating significant market penetration.
Furthermore, in another report titled “United Therapeutics Corporation: Expansion in Tyvaso To Build A Robust Foundation For Sustained Revenue!”, Baptista Research acknowledges United Therapeutics Corporation’s strong financial and developmental performance in the fourth quarter of 2024. The company achieved a record-setting year for revenue, driven by the robust growth of its treprostinil-based therapies, such as Tyvaso, Orenitram, and Unituxin. This positive sentiment from analysts on Smartkarma reflects confidence in United Therapeutics‘ strategic expansions and revenue-generating capabilities in the pharmaceutical industry.
A look at United Therapeutics Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 1 | |
| Growth | 4 | |
| Resilience | 4 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
United Therapeutics Corporation, a company focusing on developing pharmaceuticals for vascular diseases, seems to have a promising long-term outlook based on the Smartkarma Smart Scores. With a strong Growth score of 4 and Resilience score of 4, United Therapeutics shows potential for expansion and stability in the pharmaceutical industry. This indicates that the company is well-positioned to grow its offerings and navigate challenges effectively over time.
However, the company’s Dividend score of 1 implies a lower emphasis on dividend payments to investors. While the Value and Momentum scores sit at 3, reflecting a moderate assessment in terms of valuation and market trends. Overall, United Therapeutics appears to be a growth-oriented company with a solid foundation for long-term success in the pharmaceutical sector.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
